PURPOSE: This study aimed to prove the usefulness of the diagnostic plot, using the haemoglobin content of reticulocytes as a measure of functional iron deficiency (FID) and the ferritin index as a measure of iron availability, to customise anaemia treatment in cancer patients. METHODS: Based on results of this plot, cancer patients fulfilling practice guideline criteria to receive erythropoiesis-stimulating agents (ESAs) were allocated to treatment with ESAs alone, iron alone or the combination of both. Primary endpoint was the percentage of patients identified to require iron in addition or as an alternative to ESA therapy. RESULTS: Out of 303 patients screened, 286 were allocated to treatment: 204 patients were normochromic and iron replete and treated with ESAs alone, 22 had both FID and anaemia of chronic disease and were treated with ESAs and parenteral iron, and 60 were iron-depleted and treated with iron only. After 8 weeks, a haemoglobin increase >1 g/dL from baseline was shown by 56% of patients treated with ESAs alone, by 100% of patients receiving the combination, by 50% of normochromic and by 73% of hypochromic iron-depleted patients receiving iron only. Acute phase reaction did not diminish the response rate to ESAs. CONCLUSIONS: The diagnostic plot was superior to transferrin saturation and ferritin in predicting iron availability in hypochromic patients treated with ESAs and proved useful to select treatment for anaemia in cancer patients.
PURPOSE: This study aimed to prove the usefulness of the diagnostic plot, using the haemoglobin content of reticulocytes as a measure of functional iron deficiency (FID) and the ferritin index as a measure of iron availability, to customise anaemia treatment in cancerpatients. METHODS: Based on results of this plot, cancerpatients fulfilling practice guideline criteria to receive erythropoiesis-stimulating agents (ESAs) were allocated to treatment with ESAs alone, iron alone or the combination of both. Primary endpoint was the percentage of patients identified to require iron in addition or as an alternative to ESA therapy. RESULTS: Out of 303 patients screened, 286 were allocated to treatment: 204 patients were normochromic and iron replete and treated with ESAs alone, 22 had both FID and anaemia of chronic disease and were treated with ESAs and parenteral iron, and 60 were iron-depleted and treated with iron only. After 8 weeks, a haemoglobin increase >1 g/dL from baseline was shown by 56% of patients treated with ESAs alone, by 100% of patients receiving the combination, by 50% of normochromic and by 73% of hypochromiciron-depleted patients receiving iron only. Acute phase reaction did not diminish the response rate to ESAs. CONCLUSIONS: The diagnostic plot was superior to transferrin saturation and ferritin in predicting iron availability in hypochromicpatients treated with ESAs and proved useful to select treatment for anaemia in cancerpatients.
Authors: F Dati; G Schumann; L Thomas; F Aguzzi; S Baudner; J Bienvenu; O Blaabjerg; S Blirup-Jensen; A Carlström; P H Petersen; A M Johnson; A Milford-Ward; R F Ritchie; P J Svendsen; J Whicher Journal: Eur J Clin Chem Clin Biochem Date: 1996-06
Authors: C Bokemeyer; M S Aapro; A Courdi; J Foubert; H Link; A Osterborg; L Repetto; P Soubeyran Journal: Eur J Cancer Date: 2006-12-19 Impact factor: 9.162
Authors: Marcello Tonelli; Brenda Hemmelgarn; Tony Reiman; Braden Manns; M Neil Reaume; Anita Lloyd; Natasha Wiebe; Scott Klarenbach Journal: CMAJ Date: 2009-04-30 Impact factor: 8.262
Authors: Alain Toledano; Elisabeth Luporsi; Jean François Morere; Florian Scotté; Kamel Laribi; Jérôme Barrière; Philippe Huot-Marchand; Ladan Duvillié; Victor Hugo Concas; Roland Bugat Journal: Support Care Cancer Date: 2015-04-29 Impact factor: 3.603
Authors: Antonio Macciò; Clelia Madeddu; Giulia Gramignano; Carlo Mulas; Luciana Tanca; Maria Cristina Cherchi; Carlo Floris; Itaru Omoto; Antonio Barracca; Tomas Ganz Journal: Haematologica Date: 2014-09-19 Impact factor: 9.941
Authors: T Steinmetz; B Tschechne; O Harlin; B Klement; M Franzem; J Wamhoff; H Tesch; R Rohrberg; N Marschner Journal: Ann Oncol Date: 2012-10-15 Impact factor: 32.976